NVS News and Press, Novartis AG From 05/25/24

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio PR Newswire In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demons...

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo PR Newswire Secondary endpoint data for estimated glomerular filtration rate (eGF...

2024-05-24 14:48:52 ET Summary The stock of Cytokinetics, Incorporated plunged 17% in trading on Thursday, largely as the result of a somewhat botched capital raise announcement. The capital raise took a near-term buyout off the table in the short term and left many shareholders f...

2024-05-24 10:00:00 ET Summary Dodge & Cox Stock Fund seeks long-term growth of principal and income, with a secondary focus on achieving a reasonable current income. During the first quarter of 2024, international equities performed well, especially in developed markets....

2024-05-23 16:16:31 ET More on ADHD drugs New ADHD drugs could pay off for pharmaceutical companies Drug shortages in U.S. at highest level on record since 2001 Adderall shortage prompts FDA, DEA to ask for production boost Read the full article...

2024-05-19 15:05:03 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: Great Time To Divest Before It Potentially Crashes Eli Lilly Remains Expensive Here - Minimal Margin Of Safety The FTC Cracks Down On Novo Nordisk's Ozempic Biopharma M&A surges year ...

2024-05-16 15:08:23 ET More on MorphoSys MorphoSys: Hold Rating Until The Novartis Deal Closes MorphoSys AG (MOR) Q4 2023 Earnings Call Transcript MorphoSys reports Q1 results New safety risk for MorphoSys drug could complicate Novartis deal - STAT (update) ...

2024-05-15 08:45:36 ET Summary Pfizer has been a losing investment for several years, but stronger trading momentum is starting to appear. An easily covered and safety-minded 6% dividend yield is very attractive today. Undervaluation arguments to own shares also exist. PFE sto...

2024-05-14 06:30:00 ET There are many dividend stocks on the market. Some will eventually cut or suspend their payouts due to company-specific, economic, or broader market issues. Those aren't the kind of dividend stocks that investors will want to own. Instead, income-seekers should try to...

2024-05-13 17:41:32 ET More on Voyager Therapeutics Voyager Therapeutics: On Track To Deliver High Returns On Investment Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier Voyager Therapeutics, Inc. (VYGR) Q4 2023 Earnings Call Transcr...